Vanda Gets Its Answer From the FDA on Its Request for a Hearing on Hetlioz

The FDA met its March 5 deadline to provide Vanda Pharmaceuticals with the details of its decision to deny the company’s request for a hearing on an sNDA for a jet lag disorder treatment, finding “that there is no genuine and substantial issue of fact justifying a hearing.”
Source: Drug Industry Daily